Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV20-0251 in advanced solid tumors
NCT07070518Phase 2Recruiting
- Sponsor
- GV20 Therapeutics
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of GV20-0251 in solid tumor cancer, endometrial carcinoma, head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma, non-small cell lung cancer (NSCLC), sponsored by GV20 Therapeutics. Started Jul 2025; status: recruiting.
02
Drugs
GV20-0251
03
Conditions
solid tumor cancerendometrial carcinomahead and neck squamous cell carcinoma (HNSCC)colorectal adenocarcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07070518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070518.